Latest Articles

Publication Date
Ectopic Endometrium-Targeted M1 Macrophage-Derived Nanovesicles for Treatment of Endometriosis.

Endometriosis (EMs) is a common gynecological disorder in women of reproductive age, often presenting with pelvic pain and infertility. Its progression is closely linked to estrogen levels. While hormonal therapies …

Published: Sept. 8, 2026, midnight
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.

Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …

Published: Sept. 5, 2026, midnight
Choosing Between Newer GnRH Antagonist Therapies for Endometriosis - Patient Care Online

Choosing Between Newer GnRH Antagonist Therapies for Endometriosis Patient Care Online

Published: Aug. 26, 2026, 6:39 p.m.
Choosing Between Newer GnRH Antagonist Therapies for Endometriosis - Contemporary OB/GYN

Choosing Between Newer GnRH Antagonist Therapies for Endometriosis Contemporary OB/GYN

Published: Aug. 26, 2026, 12:10 p.m.
Oral GnRH Antagonists Expand Choice, Not Cure - streamlinefeed.co.ke

Oral GnRH Antagonists Expand Choice, Not Cure streamlinefeed.co.ke

Published: Aug. 21, 2026, 7:12 a.m.
Comparing GnRH Agonists and Antagonists for Endometriosis Pain - Patient Care Online

Comparing GnRH Agonists and Antagonists for Endometriosis Pain Patient Care Online

Published: Aug. 19, 2026, 1:39 p.m.
Comparing GnRH Agonists and Antagonists for Endometriosis Pain - Contemporary OB/GYN

Comparing GnRH Agonists and Antagonists for Endometriosis Pain Contemporary OB/GYN

Published: Aug. 19, 2026, 12:12 p.m.
Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.

Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and …

Published: Aug. 19, 2026, midnight
Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review.

In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …

Published: Aug. 14, 2026, midnight
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!